{"entity":{"id":"nct04640545","kind":"trial","name":"A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma","aka":[],"tldr":"A phase 1 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.","summary":"A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma is a phase 1 interventional study registered as NCT04640545 by Nanjing Leads Biolabs Co.,Ltd, with 79 participants enrolled, started 2020-05-12. Conditions recorded: Advanced Melanoma. Interventions recorded: LBL-007, Toripalimab and Axitinib Tablets.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04640545","url":"https://clinicaltrials.gov/study/NCT04640545"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["alcestobart"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04640545","phase":"1","setting":"A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":79,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04640545/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"alcestobart","kind":"drug","name":"Alcestobart","route":"/drugs/alcestobart/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}